NCT06832514View on ClinicalTrials.gov

Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

PHASE4RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Meningococcal Meningitis, Serogroup BTransgender PersonsSex Differences in Immune ResponseVaccination
Interventions
BIOLOGICAL

Serogroup B meningococal vaccine

The 4CMenB vaccine will be administered via two intramuscular (IM) injections in the non-dominant upper arm, with a one month interval.

Trial Locations (1)

9000

RECRUITING

CEVAC, University Hospital Ghent, Belgium, Ghent

All Listed Sponsors
collaborator

University Hospital, Ghent

OTHER

collaborator

Centre for Vaccinology - CEVAC

UNKNOWN

lead

University Ghent

OTHER